

NK.103.11  
Application No: 10/816,448  
Page 2 of 5

**IN THE CLAIMS:**

Please substitute the following listing of claims for the previous listing of claims.

1. (Currently amended) A method for the pulmonary administration [[of]] of a dry powder ~~drug~~ composition from a passive dry powder inhaler to the respiratory tract of a patient, the method comprising:  
providing a dry powder ~~drug~~ composition comprising particles comprising a lipid matrix and an active agent, and the particles having a particle size of 1-30 microns, mass median aerodynamic diameter of less than 5 microns, and bulk density of less than 0.5 g/cm<sup>3</sup>;  
loading the ~~drug~~ dry powder composition into a passive dry powder inhaler having a resistance of from 0.01 to 0.30 (cmH<sub>2</sub>O)<sup>1/2</sup>/Lmin<sup>-1</sup>; and  
administering the ~~drug~~ dry powder composition from the inhaler to the respiratory tract of a patient,  
wherein the emitted dose is at least 60% for flow rates from 10 to 60 liters per minute.
2. (Cancelled.)
3. (Previously presented) A method according to claim 2 wherein the emitted dose is at least 80% for flow rates from 10 to 60 liters per minute.
4. (Currently amended) A method according to claim 1 wherein the fine particle fraction, which is the fraction of the particles emitted from the inhaler as determined by an Anderson Cascade Impaction or multi-stage liquid impinger, is at least 60%.

NK.103.11

Application No: 10/616,448

Page 3 of 5

5. (Currently amended) A method according to claim 1 wherein the lipid comprises a phospholipid selected from the group consisting of dipalmitoylphosphatidylcholine, distearylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerol, ~~short-chain~~ phosphatidylcholines, ~~long-chain~~ saturated phosphatidylethanolamines, ~~long-chain~~ saturated phosphatidylserines, ~~long-chain~~ saturated phosphatidylglycerols, and ~~long-chain~~ saturated phosphatidylinositols.

6-10. (Cancelled.)

11. (Previously presented) A method according to claim 1 wherein the lung deposition is greater than 25%.

12. (Original) A method according to claim 1 wherein the lung deposition is greater than 30%.

13. (Original) A method according to claim 1 wherein the lung deposition is greater than 50%.

14. (Currently amended) A method according to claim 1 wherein the drug active agent is selected from the group consisting of budesonide, tobramycin sulfate, leuprolide acetate, Amphotericin B and PTH.

15. (Previously presented) A method according to claim 1 wherein the powder comprises hollow porous microparticles.

16-20. (Cancelled).